December 9, 2015 — Medinol U.S. recently opened their commercial business in Parsippany, New Jersey, followed by the launch of the NIRxcell CoCr Stent System.
During the recent 2015 Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco, Medinol Ltd. hosted a satellite symposium, "The BioNIR eDES: The Role of Uniformity in Stent Design to Minimize Restenosis", where a physician panel discussed the key attributes of the NIRxcell System and the Medinol eDES Coronary Stent System (in trials, not FDA/CE Mark approved). Physician faculty included David E. Kandzari, M.D., Piedmont Heart Institute; Jim Zidar, M.D., North Carolina Heart and Vascular; Rajiv Jauhar, M.D., North Shore University Medical Center; Peter Smits, M.D., Maasstad Ziekenhuis, Rotterdam, the Netherlands; and Shmuel Banai, M.D., The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Discussion highlighted key product features and emphasized the design of the BIONICS/NIREUS clinical trials that have recently completed enrollment.
Kandzari commented, "The delivery system is unlike in any other product on the market" and Medinol's approach to trial design "was entirely unlike any other pivotal trial as it included a 'more comers' patient population."
On an annual basis, approximately 800,000 patients undergo coronary stenting procedures in the United States. Healthcare providers continue to look for novel, effective and efficient solutions to treat their patients.
For more information: www.medinol.com